Este sitio requiere JavaScript para funcionar apropiadamente. Por favor modifique sus preferencias o utilice un navegador diferente para continuar.

      

Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

Single daily inhalation in an easy-to-use inhaler for COPD
1-4

Introducing TRELEGY Ellipta, the only single daily inhalation therapy for COPD that combines ICS, LAMA and LABA. 1

See dosing information

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. 1

Register today

Receive the latest information about TRELEGY Ellipta.

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long acting muscarinic antagonist; OD, once-daily

References:

  1. TRELEGY Ellipta Summary of Product Characteristics, 2017.
  2. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.
  3. Riley JH et al. Int J Chron Obstruct Pulmon Dis 2016; 11: 1873-80.
  4. Svedsater H et al. BMC Pulm Med 2013; 13: 72.


TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.

Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution